Results 111 to 120 of about 3,980 (188)

Medium-Sized Ring Expansion Strategies: Enhancing Small-Molecule Library Development. [PDF]

Molecules
Lee H, Kim J, Koh M.
europepmc   +1 more source

Copper-Catalyzed γ-C(sp³)-H Lactamization and Iminolactonization. [PDF]

Angew Chem Int Ed Engl
Sheng T, Zhuang Z, Zhao Z, Hoque ME, Yu JQ.   +4 more
europepmc   +1 more source

Chemical Diversity and Ecological Origins of Anti-MRSA Metabolites from <i>Actinomycetota</i>. [PDF]

Antibiotics (Basel)
Fernandes SP, de Almeida LLC, de Souza TA, de Oliveira GD, Silva MDS, Rodrigues-Junior VDS, Alves HDS, Cibulski SP.   +7 more
europepmc   +1 more source

Mould growth on building materials:Secondary matabolites, mycoxocins and biomarkers [PDF]

, 2001
Nielsen, Kristian Fog
core  

Real-world costs, treatment patterns, and clinical outcomes associated with treatments for advanced anaplastic lymphoma kinase-positive non-small cell lung cancer. [PDF]

J Manag Care Spec Pharm
Mudumba R, Liu X, Davis I, Romley JA, Nieva JJ.   +4 more
europepmc   +1 more source

Kinetics and management of adverse events associated with lorlatinib after 5 years of follow-up in the CROWN study. [PDF]

Oncologist
Liu G, Solomon BJ, Mazieres J, Kim DW, Cortinovis D, Inoue T, Sharma R, Thurm H, Polli A, Bauer TM.   +9 more
europepmc   +1 more source

Increased Cardiovascular Risk With Lorlatinib in Patients With ALK-Mutated Lung Cancer: A Real-World Comparative Study. [PDF]

J Am Heart Assoc
Lin CY, Su PL, Kuo CW, Tsai IL, Liu TH, Yang J, Lin CC, Lin SH.   +7 more
europepmc   +1 more source

Polymorphic Structure Determination of the Macrocyclic Drug Paritaprevir by MicroED. [PDF]

Adv Biol (Weinh)
Bu G, Danelius E, Wieske LHE, Gonen T.
europepmc   +1 more source

Can we escape from top-priority ESKAPE pathogens? [PDF]

Emerg Microbes Infect
Zeng L, Feng Y, Wang M.
europepmc   +1 more source

Total synthesis and biochemical evaluation of azumamides A–E and analogs [PDF]

, 2015
Villadsen, Jesper
core